Today, the 59th meeting of the EMCDDA Scientific Committee drew to a close and we said farewell and a heartfelt thank you to its members.
For three decades, the Scientific Committee has been an indispensable pillar of the agency, contributing significantly to its pursuit of scientific excellence. It has advised the EMCDDA Director and Management Board on the agency’s work programmes and on a wide range of scientific matters concerning its activity. It has also played a pivotal role in the risk assessment of new psychoactive substances. The body is composed of 15 high-level scientists from the EU Member States, selected through a public selection process based on scientific merit and independence.
This week, the Committee drew up its formal opinion on the EMCDDA Single Programming Document 2025–2027, explored future drug research priorities and recapped on its achievements over the years.
EMCDDA Director Alexis Goosdeel thanked the members for their invaluable contribution and updated them on the preparatory activities for the launch of the new European Union Drugs Agency (EUDA), which will begin work on 2 July this year.
Last November, the EMCDDA launched a call for expression of interest in membership of the new EUDA Scientific Committee. The current committee will continue its work until the end of June.
About the EUDA
On 2 July 2024, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) will become the European Union Drug Agency (EUDA) in accordance with Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006.
For additional information on the EUDA, please see: New legislation grants Europe stronger powers to tackle current and future drug problems
